Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Product sales, net	$ 2,513,805	$ 2,059,284	$ 6,616,414	$ 7,566,848
Cost of products sold	677,585	555,850	1,692,888	2,284,730
Gross profit	1,836,220	1,503,434	4,923,526	5,282,118
Selling, general and administrative expenses	3,064,769	2,823,765	8,968,226	9,834,781
Research and development expenses	232,056	170,478	641,235	524,472
Depreciation and amortization expense	8,574	15,896	28,735	49,798
Total operating expenses	3,305,399	3,010,139	9,638,196	10,409,051
Loss from operations	(1,469,179)	(1,506,705)	(4,714,670)	(5,126,933)
Interest income	8,008	30,600	53,513	102,669
Gain on sale of net operating losses	0	0	1,983,095	0
Loss before provision for income taxes	(1,461,171)	(1,476,105)	(2,678,062)	(5,024,264)
Net loss	(1,461,171)	(1,476,105)	(2,678,062)	(5,024,264)
Net loss attributable to noncontrolling interests	0	(9,811)	0	(33,987)
Net loss attributable to Milestone Scientific Inc.	$ (1,461,171)	$ (1,466,294)	$ (2,678,062)	$ (4,990,277)
Net loss per share applicable to common stockholders—
Basic and Diluted (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.03)	$ (0.07)
Weighted average shares outstanding and to be issued—
Basic and diluted (in shares)	79,966,833	73,730,921	80,165,181	72,374,693